Arrowhead Pharmaceuticals reported early clinical signals from RNAi candidates targeting obesity biology, including ARO‑INHBE, which produced meaningful fat‑loss when dosed in combination with Eli Lilly’s Zepbound in an interim cohort. Patients receiving the combination lost a median 9.4% body weight at 16 weeks versus 4.8% for Zepbound alone in this small dataset; the combo also drove substantial reductions in visceral and liver fat. Arrowhead characterized the data as encouraging and said select programs will advance toward Phase 2 testing, positioning RNAi approaches as potential longer‑duration competitors in the obesity market. The readouts prompt closer attention to safety, durability, and standalone activity as development moves into larger cohorts.